Company Overview
Biomea Fusion, Inc. operates as a clinical-stage company dedicated to the discovery and development of oral covalent small molecule drugs specifically designed to treat patients suffering from metabolic diseases within the United States. The firm functions within the healthcare sector, specifically the biotechnology industry, positioning itself to address significant unmet medical needs in diabetes and obesity through its proprietary pipeline. As of the latest available data, the company carries a market capitalization of $95.44M, while its annual revenue and total employee count are not disclosed in the provided financial records. The market capitalization of $95.44M indicates that Biomea Fusion is a small-cap entity, reflecting its early-stage nature where valuation is driven primarily by the potential of its lead product candidate icovamenib rather than current cash flows or established market share.
Financial Health
The company reports a net income of $-61,797,000 and an EBITDA of $-79,898,000 for the trailing twelve months, while specific revenue figures are not publicly available in the current dataset. The substantial gap between revenue and net income, alongside the negative EBITDA, reveals a cost structure heavily weighted toward research, development, and operational expenses typical of clinical-stage biotechnology firms that have not yet achieved commercial profitability. Free cash flow stands at $-42,026,876, which signifies that the company is currently burning cash to fund its development activities, resulting in limited financial flexibility until product milestones are reached or external capital is secured. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that is standard for pre-revenue or early-revenue biotech companies where fixed costs are high relative to sales volume. The balance sheet holds $55.81M in cash against $1.59M in debt, creating a scenario where liquid assets significantly exceed obligations, yet the debt-to-equity ratio of 5.38 suggests a high leverage profile relative to the company's equity base. Despite the high debt-to-equity figure, the current ratio of 5.23 indicates robust short-term liquidity, as current assets are more than five times greater than current liabilities, providing ample coverage for immediate obligations. Return on equity is -152.4% and return on assets is -73.4%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and creditors as the company prioritizes growth over immediate profitability.
Valuation Assessment
Valuation metrics for Biomea Fusion present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -1.24, implying that the market is pricing the stock based on future expectations rather than current earnings performance. The negative forward P/E and the absence of a trailing P/E suggest that the company is not yet generating positive earnings to support traditional valuation multiples, a common characteristic of clinical-stage firms awaiting catalysts. The price-to-book ratio is 3.23, indicating that the market values the company at more than three times its book value, which may reflect the perceived value of its intellectual property and pipeline assets exceeding the carrying value on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA are not applicable or are negative, with EV/EBITDA standing at -0.52, further highlighting the reliance on non-earnings-based valuation drivers. The stock has traded between a 52-week high of $3.08 and a 52-week low of $0.87, meaning the current price sits somewhere within this historical range, subject to market sentiment regarding its drug development progress. The beta value of -0.21 is anomalous for equities, suggesting an inverse correlation to the broader market or significant volatility that deviates from standard systematic risk measures.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A due to the company's lack of substantial historical revenue data or profitability, preventing a calculation of growth velocity in the traditional sense. Because the company has not generated positive earnings to distribute, there is no dividend yield or payout ratio, resulting in a 0.0% payout ratio that precludes any sustainable dividend payments to shareholders. Instead of paying dividends, the company reinvests all available capital, including its $55.81M cash reserve, directly into the discovery and development of its oral covalent small molecule drugs to advance icovamenib through clinical trials. This strategy prioritizes long-term product development and market entry over immediate income generation, creating a profile typical of speculative growth stocks that rely on successful regulatory approval and commercialization to unlock value.